Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Hong-Xiang Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Basic and Application Research of Beiyao (Heilongjiang University of Chinese Medicine), Ministry of Education, 24 Heping Road, Harb…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Drugs, Chinese Herbal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Heilongjiang Touyan Innovation Team Program, Discipline Collaborative Innovation Achievement Project of Heilongjiang Province, Wellcome Trust.
Abstract (Originalsprache)
Objective
To investigate the mechanism and pharmacological activity of (Xiaoyaosan decoction) XYSD in the treatment of NAFL (nonalcoholic fatty liver) by proteomic techniques.
Methods
C57BL/6 mice NAFL model was induced by HFD (high fat diet), and observed biochemical indicators and histopathological changes. We employed TMT (tandem mass tag) quantitative proteomics and conducted bioinformatics analysis. Additionally, an in vitro model using unsaturated FFA (free fatty acid)-induced lipid accumulation was established to discover the effect of XYSD on lipid accumulation in HepG2 cells.
Results
The results showed that XYSD improved liver index and biochemical indexes, and reversed the characteristics of liver steatosis in NAFL mice. Based on the results of in vivo proteomic enrichment analysis, we hypothesize that the activation of the PPARα signaling pathway may be a potential mechanism underlying the therapeutic effect of XYSD in treating NAFL. XYSD remarkably improved protein and gene expression of Fads2 (fatty acid desaturase 2), Hmgcs2 (3-hydroxymethylglutaryl-CoA synthase 2), Fabp1 (fatty acid-binding protein 1) and PPARα. This hypothesis has been further confirmed in our in vitro experiments.
Conclusion
The study shows that XYSD improves lipid accumulation by activating PPARα signaling pathway, and finally achieves the effect of NAFL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Basic and Application Research of Beiyao (Heilongjiang University of Chinese Medicine), Ministry of Education, 24 Heping Road, Harbin, Heilongjiang 150040, China.
- Heilongjiang Chamgree Pharmaceutical Co., Ltd., Qing'an, Heilongjiang 152400, China.
- Enzyme Engineering and Green Biomanufacturing Laboratory, College of Life Science, Northeast Agricultural University, 59 Wood Street, Xiangfang District, Harbin, Heilongjiang 150030, China.
ORCID-Profile: Jun Liang
Förderung
- Heilongjiang Touyan Innovation Team Program
- Discipline Collaborative Innovation Achievement Project of Heilongjiang Province
- Wellcome Trust
- National Key Research and Development Project of China
- Young Qihuang Scholar Project of Heilongjiang Province
Zitieren
APA
Jiang, H. X., Li, Y. G., Sun, C., Zhou, L., Wang, J., Wang, W. F., & Liang, J. (2026). Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf109
Vancouver
Jiang HX, Li YG, Sun C, Zhou L, Wang J, Wang WF, et al. Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf109
BibTeX
@article{Jiang2026,
author = {Jiang, Hong-Xiang and Li, Ya-Ge and Sun, Chao and Zhou, Lan and Wang, Jing and Wang, Wen-Fei and Liang, Jun},
title = {Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf109}
}
EUVIMED